Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pantethine→

Pantethine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
16816-67-4
Molecular formula
C22H42N4O8S2
Molecular weight
554.7 g/mol
Drug class
Pantothenic-acid-derived lipid-modulating nutrientpantetheine dimer
Mechanism of action
A dimer of pantetheine and a precursor in coenzyme A metabolism. It has been studied for effects on fatty-acid synthesis and HMG-CoA reductase activity and may modestly influence circulating total cholesterol, LDL cholesterol and apolipoprotein B.
Indications / reported uses
  • Marketed in some countries as a nutritional or adjunctive lipid-modulating product. Evidence supports only modest lipid changes in selected studies; it is not a replacement for guideline-directed lipid-lowering medication.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC5575230/ · https://pubchem.ncbi.nlm.nih.gov/#query=pantethine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pantethine Environmental Risk Assessment (ERA) (the Pantethine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.